Categories
Product

OMNY Health Achieves HITRUST e1 Certification: A Milestone in Healthcare Data Security

We at OMNY Health are thrilled to announce that the OMNY Health Platform has successfully achieved HITRUST e1 Certification, a landmark achievement in our ongoing commitment to foundational cybersecurity controls and information risk management in healthcare. 

HITRUST e1 Certification focuses on foundational cybersecurity and the most critical set of controls for essential cybersecurity hygiene. This certification demonstrates that OMNY’s Ecosystem Platform has a comprehensive set of rigorous controls and best practices in place for essential for cybersecurity hygiene and protecting sensitive information. 

“The HITRUST e1 Validated Assessment is a good tool for cyber-aware organizations like OMNY HEALTH that want to build assurances and progressively demonstrate due diligence around information security and privacy,” said Robert Booker, Chief Strategy Officer at HITRUST. “We applaud OMNY HEALTH for their commitment to cybersecurity and successful completion of their HITRUST e1 Certification.” 

Achieving HITRUST Certification is no small feat. It represents countless hours of hard work, meticulous attention to detail, and an unwavering commitment to excellence from our entire team. This certification validates our robust approach to data security and privacy, covering 19 domains of information security. 

“The HITRUST e1Certification is more than just a badge of honor – it’s a rigorous, comprehensive validation of our security practices,” said Dr. Maik Lindner, OMNY’s Chief Information Security Officer.  “This achievement demonstrates that we’ve implemented a robust set of controls that meet the unique challenges of protecting sensitive healthcare data. It’s a reflection of our proactive approach to security and our commitment to staying ahead of evolving cyber threats in the healthcare industry.” 

For our health system partners, the HITRUST Certification of our platform offers several key benefits:

  • Enhanced Trust: You can be confident that your data is protected by security measures that meet or exceed industry standards.
  • Simplified Compliance: Our certification helps streamline your compliance efforts, particularly with regulations like HIPAA. 
  • Reduced Risk: With our certified security framework, the risk of data breaches and associated costs is significantly reduced.
  • Improved Interoperability: Our certification enhances our ability to securely share and process data across the healthcare ecosystem.

“Achieving HITRUST certification is a testament to our unwavering commitment to data security and privacy in healthcare. This milestone reflects the dedication of our entire team and reinforces our position as a trusted partner in the healthcare data ecosystem. We’re proud to offer our health system partners the highest level of assurance in data protection, allowing them to focus on what matters most – improving patient outcomes,” said Dr. Mitesh Rao, CEO. 

At OMNY, we view this certification not as a final destination, but as a milestone in our ongoing journey of excellence. We are committed to:

  • Continuously improving our security measures 
  • Staying ahead of emerging threats in the digital healthcare landscape
  • Providing our partners with the highest level of data protection 

As we celebrate this achievement, we want to thank our dedicated team and our valued partners for their trust and support. We look forward to continuing our mission of advancing healthcare through secure, innovative data solutions.

Categories
Product

Does Implant Design Matter? Studying Total Knee Arthroplasty in Clinical RWD

Knee replacement surgery has advanced significantly over the years, with innovations in implant design aimed at improving patient mobility and long-term outcomes. However, when it comes to single-radius (SR) vs. multi-radius (MR) femoral implants, how much of an impact does design really have on patient recovery and healthcare utilization? While clinical trials provide controlled comparisons, real-world evidence offers a broader perspective on outcomes across diverse patient populations.

To better assess these differences, OMNY Health analyzed real-world data from its orthopedic-focused medtech dataset, evaluating clinical, functional, and economic outcomes in TKA patients.

Comparing Implant Design in Real-World Settings

This study leveraged data from the OMNY Health Medical Device Database (2017-2021), examining 1,464 patients who underwent unilateral TKA. Patients were categorized into SR (N=1,135) and MR (N=329) cohorts, allowing for direct comparisons of key outcomes.

bar chart showing demographic characteristics among patients with sickle cell

Patient Demographics:

  • Most patients were born between the 1950s and 1960s (SR: 59%, MR: 57%).
  • Women accounted for the majority of cases (SR: 63%, MR: 70%).
  • The SR cohort had a higher proportion of White patients (85%) compared to the MR cohort (75%).
  • More MR patients underwent outpatient procedures (53%) compared to SR patients (43%).

Key Findings: Minimal Differences Between Implant Designs

Despite prior speculation that implant design could significantly impact outcomes, this real-world analysis found that SR and MR implants performed similarly across key measures.

bar chart showing demographic characteristics among patients with sickle cell

Clinical Outcomes:

  • Mortality rates were low in both cohorts (SR: 1.1%, MR: 0.3%).
  • Postoperative knee pain was reported at comparable rates (SR: 0.6%, MR: 1.2%).
  • Implant removal was rare, with no significant difference observed (SR: 0.4%, MR: 0.0%).

Functional Outcomes:

  • Non-routine discharge disposition (NRDD) rates were identical (SR: 16.4%, MR: 16.4%), suggesting that implant design did not influence post-surgical mobility.

Economic & Utilization Outcomes:

  • Length of stay (LOS) was similar across groups (SR: 0.98 days, MR: 0.96 days).
  • Gross charges were slightly higher for SR patients (Median: $43,879 vs. $39,255 for MR), though differences may be driven by factors beyond implant design.

What This Means for Clinical Decision-Making

The findings suggest that implant design alone does not significantly impact clinical or functional outcomes in TKA patients. Instead, factors such as surgical technique, rehabilitation protocols, and patient-specific factors play a more substantial role in determining recovery and long-term success.

For healthcare providers and medtech companies, these results highlight the value of real-world data in refining orthopedic product development and post-market surveillance. While MR designs have been thought to provide more natural knee movement, this study suggests that real-world functional outcomes do not differ significantly between SR and MR implants.

Additionally, the slight difference in cost between implant types warrants further investigation to determine cost-effectiveness in value-based care models.

The Role of Real-World Data in Orthopedic Research

By integrating structured EHR data with curated clinical measures, OMNY Health provides real-world insights into medical device performance. This data-driven approach enables:

  • Comparisons of implant designs and surgical techniques to refine best practices.
  • Better understanding of patient recovery patterns and healthcare utilization.
  • Support for evidence-based decision-making to optimize orthopedic device selection and patient outcomes.

With orthopedics as a key therapeutic area for medtech innovation, leveraging real-world evidence is essential for ensuring high-quality, cost-effective decision-making in TKA and beyond.

Categories
Product

Unlocking Real-World Insights into IBD Treatment: The Power of Clinical EHR and Physician Notes Integration

At OMNY Health, we believe that unlocking the full potential of healthcare data means going beyond structured fields in Electronic Health Records (EHRs). By combining EHR data with unstructured clinical notes, we can uncover insights that truly reflect the complexities of patient care—insights that are often hidden in claims or EHR data alone.

Our recent study on Inflammatory Bowel Disease (IBD) treatment patterns highlights the unique value of integrating EHR data with clinical notes. Using Large Language Models (LLMs), we analyzed over 10.6 million clinical notes from our health systems to explore why IBD patients switch or discontinue biologic treatments. This approach gave us a comprehensive, real-world view of treatment decisions. We identified 7 distinct reasons for treatment alteration across 7 biologics.

Key Findings: Uncovering the Real Reasons for Treatment Changes

While traditional EHRs track structured data like medication prescriptions and diagnoses, they often miss the “why” behind treatment decisions. Our study revealed seven key reasons why biologic treatments are altered, based on unstructured notes that provide deeper context:

  • Adverse Drug Events (16-28%)
  • Finance-Related Reasons (4-24%)
  • Patient-Related Factors (2-9%)
  • Lack of Efficacy (1-14%)
  • Symptom Resolution (1-4%)
  • Drug-Disease Interactions (1-3%)
  • Obstetric Concerns (0-2%)

Figure 1. Reasons for Biologic Switching in IBD

Biologic Adverse Drug Event (%) Drug-Disease Interaction (%) Symptom Resolution (%) Finance Related (%) Patient Related (%) Not Effective (%) Obstetric (%)
Infliximab 28.26 1.92 2.87 24.42 8.62 14.37 0.48
Adalimumab 26.82 2.87 1.44 12.93 8.14 2.87 1.92
Golimumab 0.96 0 0.48 1.44 0.48 0 0
Certolizumab 1.92 0 0 0.96 0 0 0
Vedolizumab 16.28 0.96 4.31 7.18 6.70 1.44 1.92
Ustekinumab 11.01 0.48 0 3.83 2.39 0 0
Risankizumab 0.96 0 0 0 0.48 0 0

Transforming IBD Care: From Data to Insight

By analyzing clinical notes, OMNY Health’s AI models identified reasons for treatment alterations with 94.5% accuracy. This level of insight isn’t typically captured in structured EHR fields, and it has significant implications for improving patient care.

Understanding the real-world reasons behind treatment changes is essential for refining treatment strategies, improving adherence, and ultimately achieving better patient outcomes. For IBD patients, this means more personalized care tailored to their unique circumstances—whether that’s a financial hurdle, an adverse drug reaction, or a need for a more effective therapy.

The Future of Healthcare Data: A New Era of Personalized Care

At OMNY Health, we’re excited about the future of healthcare data. By integrating EHRs with unstructured clinical notes and leveraging the power of AI, we can identify patterns that were previously overlooked. This approach not only improves our understanding of IBD treatment but also has the potential to transform how we approach care across a wide range of conditions.

Categories
News

GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds

Categories
News

OMNY Health and Scipher Medicine Partner to Revolutionize Autoimmune Disease Treatment with Clinico-Transcriptomics Data

Categories
News

OMNY Health Launches Dynamic GLP-1 Network of 600,000+ Patients to Fuel Clinical Research on Its Use

New Studies on the Use of These Medications in Adult and Pediatric Populations are Supported by the Data Network

Atlanta, Georgia – August 27, 2024 – OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data partnerships, today announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, further cementing the company’s commitment to democratizing healthcare data across industries. This new data network comprised already of over half a million patients will supply its life sciences and health system partners, as well as its AI-driven health tech partners, with additional knowledge of GLP-1 use, related social determinants of health (SDOH), and patient demographics to better inform generative AI tools, researchers, and clinicians and improve patient outcomes.

Despite a staggering amount of healthcare data being generated across health systems and life sciences companies, 97% of this data goes unused. This underutilization is particularly crucial as the usage of GLP-1 agonists surge, driven by their effectiveness in treating chronic conditions such as type 2 diabetes and obesity. The growing demand for these medications has sparked an urgent need for more comprehensive data that evaluates their effectiveness and long-term effects for other conditions like cardiovascular disease, liver disease, and skin disorders.

“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole,” said Dr. Mitesh Rao, CEO of OMNY Health. “By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.”

OMNY’s GLP-1 data network consists of curated EMR data from more than 645,000 patients representing a broad set of demographic characteristics, including age ranges, race/ethnicity, region of care delivery, as well as provider and payer types. The data network supported two recent studies that address gaps in understanding GLP-1 therapies, particularly within pediatric and patient populations impacted by SDOH factors enabling partner companies to better understand and apply findings to patient treatments.

Pediatric use of GLP-1s was not approved by the FDA until December 2022, making data on these use-cases extremely limited despite the prescriptions of GLP-1RAs for children and adolescents increasing by 594.4% from 2020 to 2023. OMNY’s GLP-1 network contains valuable information on pediatric GLP-1 use, enabling a study that found the median age of users was 16 years and the majority were female in gender (72%).

“We are able to deliver more equitable clinical outcomes when the research is backed by data from diverse populations,” said Dr. Sameer Badlani, Fairview Health Services’ Executive Vice President, and Chief Strategy Officer. “With access to data that factors in SDOH for diverse populations we learn valuable insights in service of providing resources and clinical care that is differentiated by excellence in quality, safety, experience and health equity for every consumer who trusts us with their wellness and care.”

OMNY’s network also provides critical information on SDOH factors, including economic insecurity, food insecurity, and social isolation often documented in clinician notes. With many of these factors accounting for up to 50% of the variation in health outcomes in the US, it was crucial that the SDOH status of patients receiving GLP-1 treatment be made available. A second study by OMNY found that GLP-1 patients were half as likely to have SDOH economic burden issues noted in their EHR record as compared the population of non-users.

OMNY’s data network enables companies to diversify their patient populations for clinical trials, better understand medication interactions, and strengthen treatment outcomes.

This announcement follows OMNY’s partnerships with QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and the creator of LifeSphere®. OMNY Health is committed to AI-enabled healthcare improvement and supporting research programs that aim to improve clinical care. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit www.marketing-dev.omnyhealth.com.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

Media Contact:

Chloe Fredericksdorf
omnyhealth@solcomms.co.

Categories
News Product

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

OMNY Health’s GI partnerships are a pivotal step in its mission to deliver data and insights to accelerate life-changing innovation. With a focus on catalyzing research and improving outcomes, OMNY aims to make a tangible difference for the millions of individuals in the US impacted by gastroenterology diseases

ATLANTA, GA, April 22, 2024 – OMNY Health is pleased to announce its partnership with the nation’s leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY’s research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY’s real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with the health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY’s solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

“United Digestive remains committed to offering our patients the most suitable and cost- effective healthcare solutions. Our dedication to delivering best-in-class GI care is intricately linked with our data-driven approach,” says United Digestive’s Chief Medical Officer, Dr. John Suh. “We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care.”

“As Florida’s leading gastroenterology provider, Borland Groover’s mission is to provide exceptional care and improve the lives of our patients. Achieving this objective requires a deep understanding of our patients, patterns of care, outcomes, and opportunities for further improvement through data analysis,” said Borland Groover’s CEO, Dr. Kyle Etzkorn. “Our collaboration with OMNY not only aligns with our mission, but it also presents avenues to identify and pursue future opportunities for elevating GI patient care.”

“Enhancing patient care isn’t just a goal; it’s our responsibility, guided by the personal experiences of every patient we serve. Each piece of patient data is not just a statistic; it is a pathway to better outcomes, a testament to our commitment, and a source of inspiration for ongoing progress” said Christa Newton, MBA, CEO, OneGI. “We are excited to partner with OMNY as a tangible step in realizing these guiding principles for the benefit of our patients.”

“It is important to One GI that our patients are represented when it comes to emerging research, care improvement initiatives, and best in class care. Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy to access exceptional GI care.” – Dr. Michael Dragutsky, Founder, Chairman, OneGI. Key populations available in the GI specialty offerings are aligned with the significant research and development efforts underway in gastroenterology, including ulcerative colitis, Crohn’s disease, celiac disease, short bowel syndrome, reflux disorders, and many others. Like other OMNY Health specialty-focused solutions, the GI offering includes information covering pharmacy orders, lab and diagnostic test results, comorbidities, symptom checklists, and provider clinical assessment scores. “We are thrilled to welcome our new gastroenterology providers to our network. Over the past two years, we have made great strides connecting researchers and providers participating in our dermatology and ophthalmology research networks. We look forward to building on that impact in the field of gastroenterology,” said Mitesh Rao, MD, CEO, OMNY Health.

About OMNY Health

OMNY Health connects the healthcare ecosystem through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs.   The OMNY platform serves as a centralized resource for healthcare stakeholders to participate in data sharing and research services at scale, fueling innovation where patients need it the most. For more information, go to https://marketing-dev.omnyhealth.com/

MEDIA INQUIRIES: media@omnyhealth.com 

Categories
Editorial

Linking Real-World Clinical Data with Medical Device Data to Demonstrate Device Value

Real-World Data in the Medical Device Market

Many life sciences organizations are focused on harnessing real-world data (RWD) capabilities to inform every part of the drug development product life cycle. The same types of RWD can, and should, be applied to innovation around the development and measurement of the effects of medical devices. RWD derived from healthcare sources, such as electronic health records, provides insights into the burden of disease, and after a device market launch, provides insights into competitive stance, safety, efficacy, and outcomes. Traditionally, these types of analyses have been difficult to perform for medical devices because the specific details surrounding the medical device make, model, and manufacturer used in procedures are often buried in the electronic health record or other IT systems, and historically have not been collected uniformly.

Medical Devices in the Real World

Medical Devices have become a critical part of a patient’s daily life, and how patients interact with these devices can tell us a lot about their effectiveness. From joint replacements to life-saving arterial stents and pacemakers, device manufacturers are interested in the benefit-risk profiles to inform future device modifications and technological advancements, Providers can glean important evidence for the clinical effectiveness of these devices, helping to inform what devices to use in their procedures.

Medical device manufacturers are motivated to invest in new strategies to support success. According to McKinsey, despite a period of growth from 2012 through 2019, S&P medical device investments slowed during the pandemic. Recently, however, signs have been promising; in 2023, the U.S. approved more novel medical technologies than in any single year before, and revenue growth rates are starting to stabilize to pre-pandemic levels.

Aggregation of RWD to Inform Device Safety and Evidence for Effectiveness

Using relevant and reliable RWD is important for generating RWE to understand and regulate medical device usage and safety. To get a complete picture of the patient’s use and interaction with a medical device, RWD from clinically relevant sources is required to give a holistic view of the clinical experience both before device implant/initiation and after usage has been initiated. The ability to combine disparate data from multiple sources and care settings is where OMNY Health excels.

The OMNY Health Medical Device Data Advantage

OMNY Health’s Medical Device product offering is a best-in-class view into the healthcare industry’s use of medical devices in patients. Our Medical Device offering is constructed directly from our health provider data sets, with precision down to the patient encounter level. Utilizing the Unique Device Identifier (UDI) and the device version, we have partnered with the FDA’s AccessGUDID database to ensure the highest quality and completeness of data, with unrivaled recency.

OMNY Health’s Medical Device product offering linked with OMNY Health’s EHR data, can help device manufacturers and provider networks better understand and assist the patients they are servicing by examining:

  • Medical Device use and trends
  • Patient journeys and continuity of care
  • Impact of medical devices on clinical, functional, cost, and utilization outcomes
  • Safety/adverse event reporting
  • Providers who are interested in value-based contracting and making procurement decisions

Check out the Total Knee Replacement study utilizing the OMNY Health Medical Device product offering.

Contact OMNY to learn more about how our Medical Device product offering will boost your real-world evidence generation.

Categories
Editorial

Social Determinants of Health: Generating Accurate Clinical Insights Using Real-World Data

Recent innovations in healthcare analytics and patient-oriented AI demonstrate the power of leveraging real world data (RWD) to generate ecologically valid actionable insights for life sciences companies to improve patient lives and streamline new therapeutic advances. Such insights are essential for decision-making in health economics and outcomes research (HEOR) and in the clinical trial planning and implementation processes. However, the breadth, depth, and inclusivity of the data used to generate such insights can have a huge impact on both the accuracy and validity of any analyses. Various sources of bias, such as the lack of demographic and socioeconomic diversity in a cohort, can undermine the main benefit of using RWD to supplement life sciences research. To combat this, many researchers and providers have publicized the need for clinically-validated metrics that can be used to measure and quantify cohort-level bias and provide more transparency in the field.

Social Determinants of Health Data Account for Notable Variations in Clinical Outcomes

One commonly referenced set of measures that has received growing recognition is social determinants of health (SDoH) data – a set of criteria used to capture economic and social vulnerabilities across key domains. Various studies have estimated that accounting for SDoH variables, such as income level, housing security, transportation, gender identity, and race and ethnicity, can account for 40 – 60% of the variation in clinical outcomes and care patterns. A recent study examining Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) data illustrates this all too well. Researchers found that trial participants in the lowest-income trial sites had poorer blood pressure control and worse outcomes for some adverse cardiovascular events, even when treatment access and adherence were accounted for. The authors concluded that these results clearly illustrate “the importance of measuring and addressing socioeconomic context in [randomized controlled trials] RCTs.” The incorporation of these factors into studies leveraging RWD is just as important.

United States Government Support for Clinical Research and RWD Inclusivity

Researchers are not the only ones promoting the importance of SDoH – the U.S. government is facilitating efforts to foster greater inclusivity in clinical trial participation across multiple fronts. The Food and Drug Administration has issued new guidelines about the use of RWD in clinical research, pointing to the utility of inclusive data sources to identify clinical trial participants. The Centers for Medicare & Medicaid Services (CMS) are also focused on health equity. At the end of 2023, CMS released an updated framework for health equity with a focus on the collection of interoperable, standardized SDoH. As of January 2024, CMS requires the screening of five SDOH domains for admitted hospital patients.

Challenges with Obtaining and Utilizing SDoH Data

Despite the power of SDoH to create a more inclusive real-world environment for clinical trials and research analyses, patient-level SDoH data availability to pharmaceutical companies has been lacking. This is in large part due to barriers relating to extracting and aggregating relevant material. In typical healthcare systems, patient-level SDoH data are often difficult to expose and curate as the relevant information is buried in clinical codes and unstructured notes. However, the aforementioned efforts by various government entities have resulted in an exponential increase in the amount of patient-level SDoH data available in medical records – including increased use of structured surveys and other collection tools.

Much of the SDoH data currently available in the RWD marketplace rely on a combination of 3-digit zip-code-level data and aggregated claims or credit data, which only provide inferred modeled proxies, not insight into actual patient-level information. Those that are able to derive SDoH variables through direct access to EHRs often face issues such as data lags, inconsistent data collection vehicles, and gaps in reporting. OMNY Health has the technology in place at the provider level creating a direct flow of data through the OMNY platform so that data is captured consistently with limited lag time. These unique integrated partnerships with large integrated delivery networks (IDNs) and specialty networks have enabled us to quickly capitalize on the growing availability of SDoH data in patient records.

OMNY Health Top-tier SDoH Data Sets

OMNY Health is focused on creating a best-in-class SDoH data product to augment our existing EHR-derived, de-identified clinical data sets. Our ​​Social Determinants data offering is constructed from point-of-care documentation aggregated at the patient-encounter level. To ensure deep, multi-faceted coverage, we leverage multiple streams of information, including ICD-10 diagnostic codes, self-reported responses to standardized SDoH surveys, and estimated SDoH burden derived using research-grade, validated NLP models run on unstructured clinical notes.

OMNY Health’s Social Determinants data offering, when integrated with our extensive clinical data sources, can help pharmaceutical companies and provider networks better help the patients they are serving and be more successful by informing:

  • More accurate HEOR analyses
  • Inclusive clinical trial planning and implementation
  • Analysis of clinical trial results and differences in real-world populations
  • The development of precision medicine treatments
  • The understanding of the barriers to drug access and adherence and how to develop targeted programs to reduce those barriers
  • Different disease severity and outcomes across populations and geographies
  • Market access and pull-through strategies for contracting and drug promotion.

SDoH data can offer insight into the everyday non-clinical factors that influence how individuals develop diseases, respond to treatments, and participate in clinical trials.

Contact OMNY to learn more about how our SDoH data sets will boost your real-world evidence generation.

Categories
News Product

Five Natural Language Processing Subtasks that Large Language Models Can Perform to Improve Healthcare

In late 2022, the technology world was turned upside down as OpenAI released ChatGPT, its new artificial intelligence (AI) model.  Unlike most previous natural language processing (NLP) models, this model contained billions of parameters, was trained on a corpus of unstructured data with unprecedented size, and underwent a novel alignment process to better orient the model towards human needs.  The result was a model that provided superior performance for various NLP-related tasks and professional certification exams (including medical ones) and could produce realistic-sounding text that even the most hardened AI cynics could not deny.  Technological and legal impacts were felt almost immediately. Many technology companies began to invest in the new field of generative artificial intelligence (genAI) with an eye toward the potential for financial benefits. 

However, lost in all the excitement, is the fact that genAI relies largely on the bread-and-butter NLP methods and subtasks that have supported and improved many industries, including healthcare, over the past decade or two, with the additional capability of text generation.  Unlike previous NLP models, newer large language models (LLMs) can perform many different NLP subtasks with one single model. 

So, what are the different subtasks that a state-of-the-art LLM can perform? Without further ado, here are five NLP subtasks that can be programmed into LLM to improve healthcare:

Text Classification

Text classification, or the task of distributing text into categories, is often seen as the most primitive NLP subtask.  A classic non-healthcare example of this subtask is categorizing reviews (e.g., critiquing products or movies) into having positive or negative sentiments. Text can be classified at the sentence or paragraph level, depending on the use case.   

In healthcare, the clinical notes for patients can be classified as to whether they identify patients as having certain attributes or disease characteristics.  Using that information, appropriate personalized interventions and treatments can then be used to improve health.  Over the past year, work at OMNY Health has focused on several text classification projects, including the following:

  1. Classifying generalized pustular psoriasis (GPP) patients or patients with a rare, devastating form of the skin disease psoriasis, by their disease status (flare versus non-flare) in collaboration with a life sciences partner. 
  2. Classifying psoriasis patients as to whether they received joint assessments and/or rheumatology referrals in the presence of psoriatic arthritis symptoms, in collaboration with life sciences partners. 
  3. Identifying patients adversely affected by social determinants of health, including illiteracy and financial and housing insecurity. 

The results of the study are available (View Report).

Named Entity Recognition

Also known as token classification, named entity recognition (NER) involves classifying individual words or phrases as reflective of an entity, for example, a person, place, or organization.  It differs from text classification in that every word is classified, unlike text classification in which sentences and paragraphs are classified.

In healthcare, common entities detected include symptoms, medications, and protected health information (PHI). PHI may be related to individuals, such as names, addresses, and contact information, in larger efforts to deidentify clinical notes before their input in an NLP model.  In fact, at OMNY Health, more than 20 PHI entities are identified and removed from clinical text before NLP to protect patient privacy and to comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996.

Relation Extraction

Relation extraction (RE) represents a relatively more complex subtask in which the relationships between various entities are determined.  For example, if two “person” entities are detected in the text, an RE task may be used to identify whether the two entities are married.  It is usually performed downstream of an NER step.  Previously, RE tasks often required expensive annotation and labeling processes to be performed successfully, although this requirement has faded with the advent of newer LLMs that can label and annotate notes automatically.

In healthcare, RE applications include identifying patient-doctor relationships for clinical note understanding, as well as more general clinical RE to model medical knowledge ontologies such as the Systematic Nomenclature in Medicine – Clinical Terms (SNOMED-CT).  At OMNY Health, work has been performed to identify relations between detected symptom and medication entity-pairs to determine if they comprised an adverse drug event (ADE).

Closed-domain Question Answering

Closed-domain question answering is an NLP subtask in which a text is paired with a question about the text, like a reading comprehension question on a standardized exam.  The question-context pair is then passed to an NLP model, which then extracts the answer to the question from the text.

In healthcare, question-answering pipelines can be performed to extract practically any conceivable information about a patient from clinical notes, when paired with the correct prompt.  The answer can then be processed and refined using additional NLP steps.  As an example, a clinical note about medication discontinuation could be passed as input to an NLP model paired with the question, “Why was the medication discontinued?”  The answer could then be passed to a text classification model which categorizes the reason for treatment discontinuation.  At OMNY Health, we have constructed such a pipeline to determine reasons for treatment discontinuation for various medications (View Report).  A second application of question-answering is the extraction of severity scores from clinical notes for various diseases.

Text Generation

Finally, text generation is the process of composing new, original text in response to a provided prompt.

The basic mechanism revolves around predicting the next word based on the input prompt and the sequence of previously generated words.  As alluded to in the introduction, modern LLMs undergo alignment to prevent toxic, irrelevant, and/or unhelpful text from being generated. This has resulted in improved output.  Text generation can be used for open-domain question answering, in which a general prompt is provided with no corresponding answer in the context (e.g. “What is the purpose of life?”).  Text generation is also used on the downstream end of retrieval-augmented generation pipelines, in which a query first causes the NLP pipeline to filter the relevant documents in a database, extract an answer, and then generate text to present the answer to the user.

In healthcare, potential applications of text generation include helping physicians write clinical notes to ease documentation burden, as well as simplifying routine tasks for health analysts at pharmaceutical companies.  A true challenge is to accomplish these use cases while protecting patient privacy and preventing any PHI leakage in responses to prompts.  At OMNY Health, we strive to accomplish these and related use cases responsibly.

Conclusion

In conclusion, there is more to LLMs than generating text.  Combining text generation functionality with the subtasks mentioned in this article potentiates LLMs to complete powerful tasks that can help improve healthcare.